Regeneron Starts Trials of Its COVID-19 Antibody Cocktail in Humans

Society » HEALTH | June 13, 2020, Saturday // 09:33
Bulgaria: Regeneron Starts Trials of Its COVID-19 Antibody Cocktail in Humans

Regeneron Pharmaceuticals, Inc. REGN has initiated the first study on its experimental dual antibody cocktail, REGN-COV2, for the prevention and treatment of COVID-19.

This program consists of four separate study populations — hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, uninfected patients in groups that are at high risk of exposure (such as healthcare workers or first responders) and uninfected patients with close exposure to a COVID-19 patient (such as the patient's housemate). The placebo-controlled studies will be conducted at multiple sites.

The first two adaptive phase I/II/III studies are evaluating REGN-COV2 (REGN10933+REGN10987) as a treatment for hospitalized and non-hospitalized patients with COVID-19. The phase I portion will focus on virologic and safety endpoints while the phase II portion will focus on virologic and clinical endpoints. Data from the phase I and phase II studies will be used to refine the endpoints and determine size for the phase III studies.

The antibody cocktail approach may also have long-term utility for elderly and immuno-compromised patients, who often do not respond well to vaccines.

We note that the Biomedical Advanced Research and Development Authority (BARDA) partly funded REGN-COV2's preclinical development and preclinical/clinical manufacturing.

A positive outcome will significantly boost the growth prospects of the company. Regeneron’s share price has surged 64.9% in the year so far compared with 4.4% growth for the industry.

Currently, there are no FDA-approved treatments for the severe illness caused by SARS-CoV-2. The pharma/biotech sector is running a race against time to come up with treatments and vaccines to cure the contagion. Given the alarming levels of spread and severity, quite a few biotechs are developing antibodies or evaluating their approved drugs or pipeline candidates to determine if they are effective in treating the infected patients.

Regeneron has had a great year so far, soaring high and pioneering the race for a possible coronavirus treatment along with other biotechs like Gilead Sciences, Inc. GILD.

Gilead’s remdesivir is leading the race for a possible treatment of this deadly virus. The company recently reported mixed results from a late-stage study on investigational antiviral remdesivir in hospitalized patients with moderate COVID-19 pneumonia. It was recently granted regulatory approval in Japan under the brand name, Veklury, as a treatment for SARS-CoV-2 infection. The approval came under an exceptional approval pathway.

Roche too has initiated a late-stage study on its arthritis drug, Actemra/RoActemra, in combination with remdesivir, in hospitalized patients with severe COVID-19 pneumonia.

Alexion ALXN is evaluating its rare disease drug, Ultomiris (ravulizumab-cwvz), for the COVID-19 infection. Earlier, Incyte INCY initiated RUXCOVID, a global, randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of Jakafi plus SoC in patients 12 years and above with COVID-19-associated cytokine storm./Yahoo Finance

 

We need your support so Novinite.com can keep delivering news and information about Bulgaria! Thank you!

Health » Be a reporter: Write and send your article

Advertisement
Advertisement
Bulgaria news Novinite.com (Sofia News Agency - www.sofianewsagency.com) is unique with being a real time news provider in English that informs its readers about the latest Bulgarian news. The editorial staff also publishes a daily online newspaper "Sofia Morning News." Novinite.com (Sofia News Agency - www.sofianewsagency.com) and Sofia Morning News publish the latest economic, political and cultural news that take place in Bulgaria. Foreign media analysis on Bulgaria and World News in Brief are also part of the web site and the online newspaper. News Bulgaria